| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2025 |
| Sales | 370 | 610 | 0 | 0 | 0 |
| Sales Growth | -39.34% | unch | unch | unch | unch |
| Net Income | -12,830 | -13,090 | -490 | 0 | 0 |
| Net Income Growth | +1.99% | -2,571.43% | unch | unch | unch |
Peak Bio Inc (PKBO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Peak Bio Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing significant unmet needs in the areas of oncology and inflammation. The company's lead product candidate includes PHP-303. Peak Bio Co., Ltd., formerly known as Ignyte Acquisition Corp., is based in NEW YORK.
Fiscal Year End Date: 12/31